Related Experiment Video
Updated: Jun 16, 2026

Remote Neuronal Activation Coupled with Automated Blood Sampling to Induce and Measure Circulating Luteinizing Hormone in Mice
Published on: August 25, 2023
Cycles triggered with GnRH agonist: exploring low-dose HCG for luteal support
J C Castillo1, M Dolz, E Bienvenido
1Assisted Reproduction Unit, Department of Obstetrics and Gynecology, Hospital Clínico Universitario de Valencia, Blasco Ibañez Avenue 17, Valencia 46010, Spain. jccastillo@fiv-valencia.es
This study found that using a gonadotropin-releasing hormone (GnRH) agonist for ovulation triggering and low-dose human chorionic gonadotropin (HCG) for luteal support in IVF cycles is safe and effective. It achieves normal pregnancy outcomes without increasing the risk of ovarian hyperstimulation syndrome (OHSS).
Area of Science:
- Reproductive Endocrinology and Infertility
Background:
- Ovarian hyperstimulation syndrome (OHSS) is a significant risk in assisted reproductive technology cycles.
- Optimizing luteal support is crucial for successful IVF/intracytoplasmic sperm injection (ICSI) outcomes, especially in OHSS-risk patients.
Purpose of the Study:
- To evaluate the efficacy and safety of luteal support with human chorionic gonadotropin (HCG) after ovulation triggering with a gonadotropin-releasing hormone (GnRH) agonist.
- To assess pregnancy rates and the incidence of OHSS in patients at risk undergoing IVF/ICSI antagonist cycles.
Main Methods:
- A prospective study involving 192 OHSS-risk patients using a GnRH antagonist protocol.
- Ovulation was triggered with a single dose of GnRH agonist (leuproreline).
- Luteal support was provided with three doses of HCG (1000 IU, 500 IU, or 250 IU) every third day.
Main Results:
- An overall pregnancy rate of 51.8% and a clinical pregnancy rate of 43.4% were observed.
- The incidence of moderate OHSS was 4.2% (8 cases) and severe OHSS was 3.6% (7 cases).
- Late-onset severe OHSS, related to pregnancy, accounted for 85.7% of severe cases.
Conclusions:
- A single dose of GnRH agonist for ovulation triggering combined with low-dose HCG for luteal support is effective for achieving pregnancy in IVF/ICSI cycles.
- This strategy appears to maintain normal pregnancy outcomes while mitigating the risk of OHSS in high-risk patients.
Related Concept Videos
Ovarian Cycle
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
Feedback Regulation of Calcium Concentration
Various transmembrane receptors, such as G protein-coupled receptors (GPCRs), elicit a response to extracellular signals by increasing cytosolic calcium. Activated GPCRs...
Gonadal and Placental Hormones
In males, testosterone is the primary gonadal androgen. It plays a central role in the maturation of male reproductive organs — the penis and testes. Additionally, testosterone is instrumental in the development of secondary sexual characteristics — a deep voice as well as facial and pubic hair growth — and...
